Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
USRE47103E1 · kind E1 · reissue
6Cited by
6References
67Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 2, 2017 |
| Grant date | Oct 30, 2018 |
| Priority date | — |
| Expiry date | Mar 2, 2037 |
Classification
- Technology area (CPC —)General
Abstract
Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.